Drug spend drops; specialty spend to rise two-thirds

chris.truelove by Joshua Slatko (joshua.slatko@ubm.com) Total spending on U.S. medicines fell 3.5 percent on a real per capita basis in 2012 and the use of healthcare services overall ...

Study: Medicare Part D patients struggle more attaining anticonvulsants

mia.burns By Mia Burns New analysis from advisory services company Avalere Health indicates that despite anticonvulsants’ protected class status, Medicare prescription drug plans ...

BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040, for Treatment of Leukemia

barbara.lempert – Partial results expected in Q4 2013 – JERUSALEM–(BUSINESS WIRE)– BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, ...

Progenics Pharmaceuticals’ Data From a Phase 1 Study of PSMA ADC Presented

barbara.lempert Progenics Pharmaceuticals’ Data From a Phase 1 Study of PSMA ADC Presented at ASCO 2013 TARRYTOWN, N.Y., June 1, 2013 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, ...

Pfizer turns to upstart CytomX for $635M deal on armed antibody tech

John Carroll Pfizer is partnering up with South San Francisco-based CytomX Therapeutics on a discovery program, putting the biotech's R&D platform to work on finding some next-gen ...

Glaxo Probes Allegedly Fraudulent Data In Study Written By Employees

esilverman In the latest instance in which a global drugmaker has become embroiled in a scandal over published study results, GlaxoSmithKline is investigating whether a scientific ...

FDA clamps clinical hold on Pluristem PhII stem cell trial

John Carroll One of the patients enrolled in a mid-stage study for an experimental stem cell therapy from Pluristem Therapeutics suffered a severe allergic reaction, sending him to ...

GW Pharmaceuticals plc Reports 2013 Second Quarter Financial Results

barbara.lempert -Conference Call Today at 8:00 a.m. ET, 1:00 p.m. BST- London, UK, 3 June 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the ...

Vanda Sends NDA to FDA for Tasimelteon

mia.burns Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind   WASHINGTON, May 31, 2013 /PRNewswire/ ...

Pharmalot… Pharmalittle… The Weekend Nears

esilverman Once again, another working week is coming to a close. And as you know, this is our treasured signal to daydream about weekend plans. Our agenda is modest, as always, ...

Lung cancer spotlighted as prime target for new immunotherapies

Ryan McBride Even before the ASCO meeting opened today, the industry has been abuzz about the breakthrough potential of new immunotherapies to restore immune attacks on cancers. FierceBiotech ...

Feud at FDA as staffer’s safety review bucks agency line

Tracy Staton Outspoken FDA scientist Thomas Marciniak is stirring the pot again. This time, his target is angiotensin receptor blockers, or ARBs, taken by millions of people for high ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS